IOVA
Iovance Biotherapeutics Inc
13.00$
-8.4%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 925.4% | 905.6% | 1,015.5% | 100.8% | 68.0% | 61.8% | 100.8% | 94.5% | 2.1% | -115.9% | 1.4% | 45.4% | -16.3% | |
| -825.4% | -805.6% | -915.5% | -0.8% | 32.0% | 38.2% | -0.8% | 5.5% | 97.9% | 215.9% | 98.6% | 54.6% | 116.3% | |
| 18,662.3% | 18,147.3% | 11,158.5% | 199.6% | 116.6% | 98.0% | 155.9% | 132.4% | 111.4% | 79.4% | 87.5% | 64.4% | 83.2% | |
| 5,749.3% | 10,231.1% | 1,155.7% | 127.2% | 67.5% | 79.7% | 21.4% | 62.9% | 51.2% | 41.9% | 54.5% | 39.5% | 45.9% | |
| 24,411.5% | 24,351.2% | 15,549.1% | 326.8% | 184.1% | 155.7% | 244.9% | 195.3% | 238.6% | 300.5% | 212.0% | 106.8% | 209.0% | |
| -25,236.9% | -25,156.8% | -16,464.6% | -327.6% | -152.1% | -117.5% | -245.8% | -189.8% | -140.7% | -84.7% | -113.5% | -52.3% | -92.7% | |
| – | 723.2% | – | – | – | – | – | – | – | – | – | – | – | |
| -24,520.9% | -24,510.0% | -15,997.8% | -316.8% | -145.3% | -104.5% | -239.2% | -182.9% | -138.8% | -82.7% | -111.6% | -49.0% | -90.4% | |
| -265.0% | -364.9% | -196.9% | -4.7% | -2.6% | 2.1% | -3.7% | 3.3% | -3.6% | 0.2% | -0.9% | -1.4% | -1.3% | |
| -24,255.9% | -24,145.0% | -15,800.8% | -312.2% | -142.7% | -106.6% | -235.5% | -186.2% | -135.3% | -82.9% | -110.7% | -47.6% | -89.1% | |
| -22,415.4% | -22,494.6% | -14,612.2% | -281.9% | -133.1% | -88.6% | -216.8% | -163.0% | -125.5% | -78.1% | -99.6% | -39.5% | -80.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.